financetom
Business
financetom
/
Business
/
Yum! Brands Likely to Deliver 'In-Line' Q3, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Yum! Brands Likely to Deliver 'In-Line' Q3, Oppenheimer Says
Oct 10, 2024 10:17 PM

11:30 AM EDT, 10/09/2024 (MT Newswires) -- Yum! Brands ( YUM ) is likely to deliver "in-line" earnings in Q3 and Q4, indicating a more balanced near-term risk and reward into the Nov. 5 results release, Oppenheimer said in a Wednesday note.

Oppenheimer analysts Brian Bittner and Michael Tamas said the company's guidance for over 8% core EBIT growth for 2024 seems achievable with strong cost controls and easier same-store sales comparisons in the second half of 2024.

"However, headwinds to earnings upside persist based on our work and due-diligence," they said, pointing a lack of Middle-East rebound in SSS and store re-openings.

For Q3, Oppenheimer projects SSS of -0.1% and EPS of $1.40, against the Street estimates of +0.3% and $1.42, respectively.

Still, Oppenheimer kept its outperform rating on the stock with a price target of $154.

"Our Outperform rating is maintained owing to a more attractive setup into 2025 when the path for sales/profit upside becomes more clear and catalytic," the analysts said.

Price: 135.40, Change: +0.68, Percent Change: +0.50

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FibroBiologics Gets European Patent for Cancer Treatment Using Modified Fibroblasts
FibroBiologics Gets European Patent for Cancer Treatment Using Modified Fibroblasts
Oct 17, 2024
10:11 AM EDT, 10/16/2024 (MT Newswires) -- FibroBiologics ( FBLG ) said Wednesday it has received a new patent from the European Patent Office for a cancer treatment method that uses modified fibroblasts to deliver anti-cancer agents. The patent covers methods to enhance fibroblasts' ability to target tumors and deliver cancer-fighting agents by leveraging their natural capacity to penetrate tumors...
Toyota, Boston Dynamics Launch Partnership for Robotics Research
Toyota, Boston Dynamics Launch Partnership for Robotics Research
Oct 17, 2024
10:08 AM EDT, 10/16/2024 (MT Newswires) -- Toyota's ( TM ) Toyota Research Institute and Boston Dynamics said Wednesday they are launching a partnership to advance robotics research. The partnership, which aims to accelerate the development of humanoid robots, will use Toyota Research Institute's large behavior models and Boston Dynamics' Atlas robot, the companies said. Financial details weren't provided. Price:...
Looking At Citigroup's Recent Unusual Options Activity
Looking At Citigroup's Recent Unusual Options Activity
Oct 17, 2024
Whales with a lot of money to spend have taken a noticeably bullish stance on Citigroup ( C ). Looking at options history for Citigroup ( C ) we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations and 40% with bearish. From...
Solar panel maker Maxeon says George Guo to succeed Mulligan as CEO
Solar panel maker Maxeon says George Guo to succeed Mulligan as CEO
Oct 17, 2024
Oct 16 (Reuters) - Renewable energy company Maxeon Solar Technologies ( MAXN ) said on Wednesday its chief executive officer Bill Mulligan will retire at the end of January next year, after nearly two years in the role, and will be succeeded by George Guo. Guo, former CEO of TCL Communication, has assumed the role at Maxeon and joined its...
Copyright 2023-2026 - www.financetom.com All Rights Reserved